The transcription factor Wilms' tumor gene 1, WT1, is implicated both in normal developmental processes and in the generation of a variety of solid tumors and hematological malignancies. Physical interactions of other cellular proteins with WT1 are known to modulate its function. We previously identified the Krü ppellike zinc-finger protein, ZNF224, as a novel human WT1-associating protein that enhances the transcriptional activation of the human vitamin D receptor promoter by WT1. Here, we have analyzed the effects of WT1 -ZNF224 interaction on the expression of apoptosis-regulating genes in the chronic myelogenous leukemia (CML) K562 cell line. The results demonstrated that ZNF224 acts in fine tuning of WT1-dependent control of gene expression, acting as a co-activator of WT1 in the regulation of proapoptotic genes and suppressing WT1 mediated transactivation of antiapoptotitc genes. Moreover, the DNA damaging drug cytosine arabinoside (ara-C) induces expression of ZNF224 in K562 cells and this induction enhances cell apoptotic response to ara-C. These findings suggest that ZNF224 can be a mediator of DNA damage-induced apoptosis in leukemia cells.
INTRODUCTION
Wilms' tumor gene 1, WT1, which is essential for the embryonic development of several organs and structures, encodes multiple isoforms of DNA-binding protein with zinc-finger domain (1, 2) . Two major isoforms of WT1 protein are designed WT1(+KTS) and WT1( -KTS), because of the insertion or exclusion of three amino acids (KTS) between the third and fourth zinc fingers; WT1( -KTS) appears to act mainly as a transcriptional factor, whereas WT1(+KTS) is involved in RNA processing (3, 4) .
WT1 is expressed in many tissues, including a small subset of hematopoietic stem cells (5) . Overexpression of WT1 has been observed in a wide range of solid tumors and hematopoietic malignancies, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in blastic phase (6 -8) , as well as in myelodysplastic syndrome (MDS) (9, 10) .
The expression of the transcription factor WT1 in leukemic cells was proposed to exert anti-apoptotic effects (11, 12) . Several genes playing a central role in the control of apoptosis have been proposed as targets of WT1, including the proapoptotic bcl-2 family members, Bax and Bak (13, 14) , bcl-2 itself (15) , and the anti-apoptotic genes A1/Bfl-1 (16) and bag3 (17) .
However, despite the identification of these target genes, little is still known about the molecular mechanism through which WT1 exerts its regulatory effect on leukemia cell apoptosis.
The regulatory properties of WT1 are complex since this transcription factor elicits both activator and repressor functions, depending on the cellular context and interactions with co-factors. An increasing number of interacting partners has been proposed to regulate its function, acting as either co-activators or co-repressors (18) . We recently identified the Krüppel-like zinc-finger protein, ZNF224, as a novel WT1-associating protein that enhances the transcriptional activation of the vitamin D receptor (VDR) promoter by WT1 in the chronic myelogenous leukemia (CML) K562 cell line (19) . This finding prompted us to search for other genes potentially regulated by the WT1/ZNF224 complex in leukemic cells.
In this study, we demonstrated that ZNF224 inhibits WT1-mediated transcriptional activation of the anti-apoptotic bag3 gene, recently identified as a novel WT1 target gene (17) . Moreover, by short hairpin RNA (sh-RNA)-mediated knock-down and overexpression of ZNF224 in K562 cells, we demonstrated that ZNF224 regulates WT1 activity at several WT1 target genes, acting as a co-activator of WT1 in the regulation of proapoptotic genes and suppressing WT1-mediated transactivation of anti-apoptotic genes.
Furthermore, we observed that ZNF224 itself could be modulated by cytosine arabinoside (ara-C), a drug widely used in the treatment of myeloid leukemia (20) and that ZNF224 overexpression increases susceptibility to apoptosis of K562 cells. Our findings demonstrated the role of ZNF224 -WT1 interaction in the modulation of apoptotic genes expression and suggest that the increased expression of ZNF224 may represent an important event in the ara-C mediated-induction of apoptosis. Collectively, data from this paper disclose a previously unrecognized, novel function of ZNF224 in the regulation of WT1-mediated transcription of genes involved in apoptosis, paving the way to potential strategies for treatment of leukemia.
RESULTS

ZNF224 represses WT1-mediated bag3 expression
We recently reported a specific nuclear interaction between ZNF224 and WT1 and demonstrated that this interaction enhances WT1-mediated transactivation of VDR promoter, thus implying that ZNF224 acts as a transcriptional co-regulator of WT1 (19) .
In this work, we investigated whether ZNF224 also affects WT1-dependent transcriptional regulation of the antiapoptotic bag3 gene expression, recently identified as a novel target of WT1 (17) . To this aim we used an HEK293 cell clone, which does not express endogenous WT1, while stably expressing ZNF224 (CL13 clone) (21) and a C3.3 clone stably expressing a small hairpin RNA (shRNA) specific for ZNF224. As control, we used a clone generated by stable transfection of HEK293 cells with the empty vector (CN2 clone) (21) . The expression level of ZNF224 in these clones is shown in Figure 1A . CN2, CL13 and C3.3 clones were transfected with increasing amounts of the WT1(-KTS) expression vector and bag3 expression was evaluated at mRNA and protein levels by quantitative real-time-PCR and western blot analyzes, respectively. A progressive increase in bag3 mRNA and protein levels was observed in CN2 clone (Fig. 1B lanes 1, 4, 7 and Fig. 1C left panel) , thus confirming that WT1 activates bag3 gene expression (17) . Conversely, in CL13 clone, overexpression of ZNF224 considerably abolished WT1-mediated bag3 induction, as indicated by down-modulation of bag3 transcript and protein expression ( Fig. 1B lanes 2, 5, 8 and Fig. 1C middle panel) . In C3.3 clone, silenced for ZNF224, the increase in bag3 mRNA and protein was higher than in CN2 clone (Fig. 1B  lanes 3, 6, 9 and Fig. 1C right panel) , thus indicating an increased transactivation of WT1 on bag3 gene in the absence of ZNF224.
To further investigate the effects of ZNF224 on bag3 gene transcription, we introduced a luciferase reporter plasmid containing bag3 gene promoter into CN2, CL13 and C3.3 clones, in the presence of increasing amounts of WT1( -KTS) expression plasmid. Analysis of luciferase activity shows that WT1 was able to activate bag3 promoter in a dose-dependent manner in CN2 (Fig. 2B lanes 10, 13, 16 ) as opposed to CL13 (Fig. 2B lanes 11, 14, 17) , in which we observed a dosedependent decrease of WT1-mediated transcriptional activity. As expected, in C3.3 clone an increased luciferase activity with respect to CN2 clone (Fig. 2B lanes 12, 15, 18 versus  lanes 10, 13, 16 ) was observed. These findings indicate that ZNF224 suppresses bag3 gene expression by a transcriptional mechanism.
ZNF224/WT1 interaction modulates the expression of apoptosis-regulating genes in K562 cells
To further confirm that WT1/ZNF224 complex modulates bag3 expression and to better characterize its role in leukemic cells, we evaluated the effects of the knock-down of ZNF224 on the expression of WT1 target genes. To this aim, K562 cells were transfected with two different shRNA plasmids targeting ZNF224 and a negative control shRNA. The knockdown of ZNF224 leads to a dramatic increase in bag3 and A1/Bfl1 anti-apoptotic mRNAs expression, whereas it causes a decrease in Bak and Bax mRNAs expression, as already previously observed for VDR, another pro-apoptotic WT1 target gene (19) (Fig. 3A) . The aldolase A mRNA was used as a control, being known the role of transcriptional repression exerted by ZNF224 on aldolase A gene transcription (22) ; as expected, ZNF224 silencing produced a considerable increase in aldolase A mRNA expression (Fig. 3A) . The changes observed in mRNAs expression after ZNF224 RNAi were confirmed at the protein levels by western blotting (Fig. 3B) .
To further verify that ZNF224, besides its role as transcriptional repressor, may act as a cofactor of WT1, we generated a pool of K562 cells stably transfected with ZNF224 ( Fig. 3C ) and evaluated the mRNA levels of WT1 target genes. As shown in Figure 3E , ZNF224 overexpression is accompanied by a decrease in bag3 and A1/Bfl1 mRNAs expression and an increase in Bak, Bax and VDR mRNAs expression. The decrease in aldolase A mRNA expression was used as a control of ZNF224 overexpression (Fig. 3E) .
We next confirmed that the ZNF224-mediated modulation of apoptotic genes was dependent on WT1 expression in K562 cells. To this aim we transiently transfected a pool of K562 cells overexpressing ZNF224 with WT1 shRNA plasmid (Fig. 3D) . The depletion of WT1 in this pool of cells affects the apoptotic gene expression, demonstrating that ZNF224 requires WT1 to modulate the expression of bag3, A1/Bfl1, Bax, Bak and VDR (Fig. 3E) . On the other hand, the expression of aldolase A, a direct target of ZNF224 transcriptional repression, was not influenced by WT1 knock-down (Fig. 3E) .
The above-reported experiments indicate that ZNF224 cooperates with WT1 in the transcriptional modulation of apoptosis-regulating genes, enhancing gene activation mediated by WT1 on pro-apoptotic genes and inhibiting WT1-mediated transcriptional activation of anti-apoptotic genes.
WT1 recruits ZNF224 to the promoter of apoptosis-regulating genes
To determine whether WT1 recruits ZNF224 on endogenous WT1 target genes we performed chromatin immunoprecipitation (ChIP) experiments. HEK293 cells were transfected with an expression vector for ZNF224 (p3xFLAG-ZNF224) (Fig. 4A) , or an expression vector for WT1 (pcDNA3WT1 (-KTS) (Fig. 4B) , or co-transfected with pcDNA3WT1(-KTS) and p3xFLAG-ZNF224 (Fig. 4C ) and chromatin was immunoprecipitated with FLAG ( Fig. 4A and C) or with WT1 antibodies (Fig. 4B ). As expected, we observed by PCR analysis that ZNF224 was bound to the aldolase A gene promoter (AldA) and not to the promoter regions of WT1 target genes (Fig. 4A) , thus indicating that ZNF224 alone was unable to directly bind to these WT1 target promoters; furthermore, WT1 was bound to Bax, Bak, A1/Bfl1 and bag3 promoter regions and not to AldA (Fig. 4B ). When ZNF224 was overexpressed along with WT1, it binds WT1 target gene promoters, thus demonstrating that WT1 recruits ZNF224 on these promoters (Fig. 4C) . No bands were observed when a G3PDH fragment was amplified, using the same chromatin samples immunoprecipitated with FLAG ( Fig. 4A and C) or with WT1 antibodies (Fig. 4B) , thus demonstrating the specificity of chromatin immunoprecipitation.
This result provides experimental evidence that WT1 and ZNF224 interact at chromatin level, and this interaction does not involve direct DNA binding of ZNF224.
Ara-C induces ZNF224 expression in K562 cells
Because the above-reported findings suggest that WT1 -ZNF224 interaction plays a relevant role in apoptotic genes expression, we decided to investigate whether ZNF224 itself could be modulated by chemotherapeutic agents. We chose cytosine arabinoside (ara-C) because it is one of the key drugs for treatment of leukemia.
K562 cells were exposed to increasing concentrations of ara-C (0.25, 0.50, 1 mM) for 24, 48 and 72 h after which cell viability and ZNF224 mRNA levels were measured (Fig. 5) . We observed that exposure to ara-C induced a time-dependent cell death ( Fig. 5A -C) .
Then, we evaluated ZNF224 mRNA levels by quantitative real-time-PCR ( Fig. 5D -F ). In accordance with our previous findings that ZNF224 induced pro-apoptotic genes expression, we observed that levels of this factor also increased in a time dependent fashion and, apparently, an inverse relationship subsisted between cell viability and ZNF224 levels. Surprisingly, a dose-dependent effect of ara-C on cell viability was not observed, even if a dose-dependent increase of ZNF224 was measured. Measurement of cell death by DAPI incorporation and annexin V binding confirmed the lack of a To confirm that leukemic cells died by apoptosis, K562 cells were cultured with or without 1 mM ara-C for 72 h after which we evaluated sub-G1 DNA content and annexin V binding by FACS analysis and the caspase 3 activition by western blot. We found that time-dependent increase in ZNF224 mRNA expression was accompanied by timedependent induction of apoptosis and caspase-3 activation ( Fig. 6A-C) , thus suggesting that caspase-3 activation was a direct consequence of ZNF224 induction.
Next, we confirmed that the increase of ZNF224 in ara-C-treated K562 cells is accompanied by an increase of proapoptotic VDR, Bax and Bak, and the decrease of antiapoptotic bag3 and A1/Bfl-1, as measured by quantitative real-time-PCR and western blot analysis ( Fig. 7A and B) .
In addition, ara-C was ineffective in inducing pro-apoptotic gene expression in pools of K562 cells silenced for ZNF224 (Fig. 7C ), notwithstanding the decrease in WT1 mRNA expression ( Fig. 7A and B) , thus confirming the role of ZNF224 as an important mediator of the ara-C-induced activation of pro-apoptotic genes.
ZNF224 overexpression enhances the apoptotic effect mediated by ara-C in K562 cells
Next, we evaluated the apoptotic response to ara-C in pools of K562 cells stably overexpressing ZNF224 (ZNF224-FLAG) or ZNF224-silenced (ZNF224 silencing) or overexpressing WT1( -KTS).
These pools of clones and their corresponding controls were cultured with or without 1 mM ara-C for 72 h and then viability and apoptosis were analyzed.
As shown in Figure 8A and D, K562 cells expressing ZNF224 -FLAG were significantly more sensitive to the effects of ara-C on cell viability and apoptosis with respect to K562 cells not expressing ZNF224 -FLAG. According to these findings, silencing of ZNF224 increased cell viability and reduced the number of annexin V-positive cells after exposure to ara-C ( Fig. 8B and E) . These results support a role for ZNF224 in the apoptotic response to ara-C.
Moreover, we observed that WT1( -KTS) overexpressing K562 cells are protected, at least partly, from cell death further confirming the anti-apoptotic role of WT1 ( Fig. 8C  and F ).
DISCUSSION
Regulation of apoptosis is a critical function of WT1 and is due at least in part to the modulation of expression of bcl-2 family members (23) . WT1 is highly expressed in leukemia cells and its overexpression is associated with a poor response to therapy (24, 25) . We recently showed that WT1 positively regulates the expression of the anti-apoptotic gene bag3, by a transcriptional mechanism. WT1-mediated increase in 9) . After 48 h cells were collected and relative luciferase activities were calculated, with the activity of control cells set as 1 (lanes 7 -9) (triplicate determinations). The effect of WT1 on bag3 promoter in CN2, CL13 and C3.3 clones is shown. pGL4-null empty vector activity indicates the background (lanes 4-6) and pCMV-LUC was the positive control (lanes 1 -3). Error bars represent standard deviations of three independent experiments. (C) WT1(-KTS) protein overexpression was evaluated by western blot analysis. G3PDH was used as loading control. Molecular weight to the left.
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BAG3 protein levels contributes to the pro-survival role of WT1 in leukemic cells (17) . The effects of WT1 on target gene expression appear to be isoform-specific, strongly influenced by different cellular contexts and by physical interactions with other proteins that are known to modulate WT1 transcriptional function (18, (26) (27) (28) . We previously identified the Krüppel-like zinc-finger protein, ZNF224, as a novel WT1-interacting factor involved in WT1 transcriptional regulation of VDR promoter (19) . In this study, we provide further evidence of ZNF224 acting as a transcriptional co-regulator of WT1 and playing a relevant role in the control of WT1-mediated expression of apoptosis-regulating gene in the CML cell line K562, thus pointing to a role for the ZNF224/WT1 interaction in leukemia. Indeed, chromatin immunoprecipitation assays revealed that ZNF224 binds to the promoter of WT1 target genes only if recruited by WT1 itself, thus indicating that ZNF224 acts as a transcriptional cofactor of WT1, without directly binding to promoter DNA sequences. A combination of over-expression and knock-down analyses of both ZNF224 and WT1 in K562 cell line revealed that ZNF224 exerts a dual effect on the expression of WT1 target genes, acting as a co-activator of WT1 in the regulation of pro-apoptotic genes and suppressing WT1-mediated transactivation of anti-apoptotic genes.
These data demonstrate that ZNF224, beyond its known role of DNA-binding transcriptional repressor (22) , may act in a DNA binding-independent mode of transcriptional regulation, through its ability to interact with another transcription factor, i.e. WT1. Our finding thus reveals a still undiscovered function for ZNF224 as transcriptional co-regulator.
However, we cannot rule out that ZNF224 could participate in the regulation of apoptosis also through the direct binding to promoters of not yet identified target genes, where it acts as a repressor.
Other Krüppel-like zinc-finger proteins are involved in cell proliferation, apoptosis and neoplastic transformation (29) . For instance, ZBP-89 has been show to be an important regulator in apoptosis and cell growth and can induce apoptosis through mechanisms both dependent and independent of p53 (30); ZNF23 inhibits cell cycle progression via up-regulation of p27kip-1 (31); APAK (ATM ad p53 associated KZNF protein) specifically inhibits p53-mediated apoptosis (32); ZNF382 exerts a pro-apoptotic role by repressing NF-KB and AP1 signaling and by inhibiting the expression of multiple oncogenes, including the NF-kB upstream factors STAT3, STAT5B, ID1 and IKBKE (33) .
Although KRAB-containing zinc-finger proteins are thought to function mainly as transcriptional repressors, it has been * P ¼ 0.05 versus scrambled shRNA; * * P , 0.002 versus scrambled shRNA; ns, not significant (B) Total protein extracts were analyzed by western blot with the indicated antibodies. G3PDH was used to monitor equal loading conditions. One representative result out of three performed is presented. Molecular weight to the left. (C) Western blot analysis showing the expression of ZNF224-FLAG protein in pool of K562 cells stably transfected with the expression vector p3XFLAG-ZNF224 (+) or with p3XFLAG empty vector used as control (2) . G3PDH was used to monitor equal loading conditions. Molecular weight to the left. (D) Western blot analysis of WT1 protein level in pool of K562 cells stably transfected with the expression vector p3XFLAG-ZNF224 and transiently transfected with WT1 shRNA (+) or with non-silencing scrambled shRNA used as control (2) . G3PDH was used to monitor equal loading conditions. Molecular weight to the left. (E) RT-qPCR analysis of mRNA levels in pool of K562 cells overexpressing ZNF224 (pool ZNF224-FLAG), or in pool of K562 cells overexpressing ZNF224 and transiently transfected with WT1 shRNA (pool ZNF224-FLAG + WT1 shRNA). The empty vector used as control was: pool of K562 stably transfected with p3XFLAG for the pool ZNF224-FLAG; pool of K562 cells overexpressing ZNF224 and transiently transfected with scrambled shRNA for the pool ZNF224-FLAG + WT1 shRNA. Error bars represent standard deviations of three independent experiments. * P , 0.05 versus control; * * P ¼ 0.004 versus control; ns: not significant.
recently reported that ZBRK1 and ZNF263 display activating as well as repressing effects on target gene transcription, by yet unknown mechanisms and co-regulators (34, 35) . Indeed, several lines of evidence indicate that specific transcription factors can use distinct combinations of co-regulator complexes and enzymatic activities required for modifying chromatin machinery, in a cell-, gene-, and promoter-specific manner.
Deciphering the role of ZNF224 as a transcriptional regulator of WT1, identifying additional components of the WT1/ ZNF224 complex and elucidating how alterations of the WT1/ZNF224 complex affect the expression of apoptosisregulating genes will shed further light into the molecular mechanisms of apoptosis regulation.
Furthermore, our study revealed that exposure of K562 cells to ara-C increased ZNF224 transcript in a time-and dosedependent manner, suggesting an important role for the anti-leukemic drug in regulating expression of this protein. ZNF224 induction is associated with an increase in apoptotic cell death, which correlates with down-regulation of antiapoptotic WT1 target genes such as bag3 and A1/Bfl1 and upregulation of proapoptotic molecules such as VDR, Bax and Bak.
On the other hand, the lack of correlation between cell death values and ara-C doses may be due to a concomitant activation mechanisms, responsible for apoptosis resistance, that hamper the expected cell death increase. Such an hypothesis is in accordance with the notion that K562 are resistant to ara-C induced cell death (36) .
Finally, notwithstanding the heterogeneity of pool of clones, the increased sensitivity to ara-C induced apoptosis in pools of clones overexpressing ZNF224 is a further element in support of the pro-apoptotic role of this zinc-finger protein. WT1( -KTS) overexpression was able to counteract, at least in part, the proapoptotic effect of ZNF224 following ara-C stimulation, thus confirming the relevant role of ZNF224/ WT1 interaction in fine tuning of apoptotic-gene expression.
Taken together, our data support a relevant role for ZNF224 in ara-C induced apoptosis of leukemia cells and suggest that ZNF224 could provide a critical link between ara-C induced DNA-damage and the expression of pro-apoptotic genes in leukemia cells.
A better definition of the molecular mechanism coupling ara-C-induced DNA damage to the initiation of cell death could lead to the development of new therapeutic drugs used for the treatment of leukemia.
MATERIALS AND METHODS
Cell culture and stable transfection
HEK293 human cell lines were cultured in Dulbecco's modified Eagle's medium (Bio-Whittaker, Verviers, Belgium) supplemented with 10% fetal calf serum, 100 mg/ml streptomycin-penicillin Figure 4 . ZNF224 is recruited by WT1 to apoptotic target gene promoters. Chromatin immunoprecipitation assay was performed with anti-FLAG antibody (A and C) or anti-WT1 antibody (B). Immunoprecipitation with non-specific IgG were used as negative control. Non-immunoprecipitated chromatin was used as total input control. PCR analysis was used to evaluate the WT1 and ZNF224 binding to AldA, A1/Bfl-1, bag3, Bax and Bak promoter regions, using specific primers. As control of specificity of immunoprecipitated chromatin, PCR was performed using G3PDH primers. Results are representative of two independent experiments. Size, in bp, of the PCR products to the left. (D) Total protein extracts from HEK293 transfected with p3XFLAG-ZNF224 and from HEK293 co-transfected with p3XFLAG-ZNF224/pcDNA3WT1(-KTS) were analyzed by western blot with the indicated antibodies. G3PDH was used to monitor equal loading conditions. Molecular weight to the left. mix (Bio-Whittaker) at 378C in 5% CO 2. The stable clone from HEK293 expressing p3XFLAG-ZNF224 (CL13) and clone from HEK293 cells transfected with empty p3XFLAG (CN2) were obtained as described (21) .
The chronic myeloid leukemia cell lines K562 were cultured in RPMI 1640 supplemented with 10% fetal calf serum and 100 mg/ml penicillin-streptomycin mix (Bio-Whittaker) at 378C in 5% CO 2 . To obtain pools of clones permanently expressing 3XFLAG-ZNF224, K562 cells were transfected with p3XFLAG-ZNF224 G418-selectable plasmid using HiPerFect Reagent (Qiagen, Hilden, Germany). Transfected cells were selected in medium containing 800 mg/ml G418 (Promega, Madison, WI, USA) for 4 weeks. Dead cells were removed by Ficoll density gradient centrifugation (GE Healthcare Bio Science AB, Sweden, Uppsala). The positive pool of clones was analyzed by western blotting using M2 anti-FLAG antibody (Sigma-Aldrich, MO, USA). As negative control, we selected pools of K562 cells stably transfected with the empty p3XFLAG G418-selectable plasmid.
We used pool of K562 cells transduced with a retroviral vector encoding for WT1( -KTS) or with the control empty vector (pMIG), as described (37) .
ShRNA-mediated knock-down
To obtain stable ZNF224 gene silencing (clone C3.3), we transfected 2 × 10 6 HEK293 cells with 10 mg of short interfering RNA plasmid SH2351C3 (ZNF224 shRNA) (Open Biosystems, Huntsville, AL, USA), using Lipofectamine Reagent (Invitrogen, Carlsbad, CA, USA), according to the manifacturer's protocol. The cells were grown in selective medium until colony formation. Positive clones were analyzed by western blotting using anti-ZNF224 antibody (T3). Pools of K562 clones silenced for ZNF224 (ZNF224 shRNA) were obtained by transfection of 1.5 mg of short-interfering RNA plasmid SH2351C3 (Open Biosystem) using the HiPerFect Reagent (Qiagen), according to the manufacturer's protocol; transfection of a non-silencing shRNA (scrambled shRNA) was used as negative control (Open Biosystem). Transfected cells were selected in medium containing 500 mg/ml Puromycin (Promega) for 4 weeks. Dead cells were removed by Ficoll density gradient centrifugation (GE Healthcare). Positive clones were analyzed by western blotting using anti-ZNF224 antibody (T3).
K562 cells were transiently transfected using the HiPerFect Reagent (Qiagen) in 12-well plates with 1.5 mg of the shortinterfering RNA plasmid SH2351C3 to silence ZNF224, or 1.5 mg of the short-interfering RNA plasmid SH25dE-10 to silence WT1, or 1.5 mg of non-silencing negative control (scrambled shRNA) as control. All plasmids were purchased from Open Biosystems. Cells were collected 48 h after transfection.
RNA isolation, reverse transcription and real-time PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol. One microgram of each RNA was reverse transcripted using QuantiTect Reverse Transcription Kit (Qiagen), according to the manufacturer's protocol. Real-time PCR was carried out in a iCycler Thermal Cycler (BioRad, Berkeley, CA, USA) using the SYBR Green I Master Mix (BioRad) and specific primers for: ZNF224 (Fw 5 
. b-actin housekeeping gene was used as a reference gene for relative quantification. All real-time PCR reactions were performed in duplicate.
To analyze the expression of ZNF224 mRNA levels in K562 cells treated with ara-C and in the untreated controls, total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. 0.5 mg of total RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc., Foster City, CA, USA) with random hexamer primers according to the manufacturer's instructions. Quantitative PCR was carried out using TaqMan probe-based chemistry (Applied Biosystems); the probe for ZNF224 (Hs00273760) and the endogenous control b-actin (Hs99999903_m1) were purchased as Assay-on-Demand (Applied Biosystems). The amplification reactions were all performed in triplicates in an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Data were collected and analyzed using the Sequence Detector v.1.1 software (Applied Biosystems).
The relative quantification in gene expression was determined using the DDC T method (38) . Normalization:
The efficacy of the PCR amplification of controls and test was identical; parallelism of standard curves of the control and test was confirmed.
Statistical analysis
P-value was determined by Student's t test. All P-values were considered significant when P , 0.05.
Transient transfection and luciferase-reporter assays
The HEK293 stable clones CL13, CN2 and C3.3 were transiently transfected using Lipofectamine Reagent (Invitrogen) in 12-well plates with 0.2 mg of a luciferase reporter plasmid containing the proximal bag3 promoter (PromBag3-Luc) and 0.4, 0.8 and 1.2 mg of WT1(-KTS) expression plasmid. The pGL4-null empty vector (0.2 mg) was used to evaluate the background luciferase activity, whereas the pCMV-LUC (50 ng) was the positive control for the assay. To normalize the luciferase assay a pRL-CMV plasmid (20 ng) coding for the renilla luciferase was used. The Dual-Luciferase Reporter Assay System (Promega Corporation, WI, USA) was performed 48 h after the transfection according to manufacturer's instructions. Results are representative of two independent experiments.
Western blot analysis
Total protein extract was obtained as follow: cells were washed twice with cold PBS, then were lysed in lysis buffer (10 mM HEPES pH7.8, 250 mM NaCl, 5 mM EDTA pH 8.0, 1% Nonidet P-40, 1 mM sodium orthovanadate and 50 mM sodium fluoride) and protease inhibitors [1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml aprotinin and 1 mg/ml pepstatin A] for 30 min on ice. The extract was centrifuged in a microfuge at maximum speed for 10 min and the supernatant was quantified using the BioRad protein assay reagent, resolved on SDS -PAGE and then transferred to Hybond membranes (Amersham Biosciences, NJ, USA). Non-specific binding sites were blocked for 2 h with 5% milk in TrisTween buffered saline (tTBS) (5 mM Tris pH 7.5, 15 mM NaCl, 0.1% Tween-20), washed three times with tTBS and incubated with the following antibodies:
anti-FLAG (M2) from Sigma-Aldrich, 1:1000 anti-VDR (D-6) from Santa Cruz Biotechnology, 1:500 anti-GAPDH (7-B) from Santa Cruz Biotechnology, 1:1000 anti-BAX (B-9) from Santa Cruz Biotechnology, 1:500 For these primary antibodies the secondary antibody was goat-anti-mouse IgG (H+L)-HRP conjugated (BioRad170-6516) antibody, 1:3000, detected with an ECL western blot detection system (Amersham Biosciences). For these primary antibodies, the secondary antibody was goat-anti-rabbit IgG (H+L)-HRP conjugated (BioRad170-6515) antibody, 1:3000, detected with an ECL western blot detection system (Amersham Biosciences).
The western blot for ZNF224 was performed using the anti-ZNF224 (T3) antibody (Rabbit polyclonal antibody) (39) . Non-specific binding sites were blocked for 2 h in SuperBlock blocking solution buffer in PBS (Thermo Scientific) with 0.1% Tween-20. SuperBlock blocking solution buffer was used in incubation steps with primary and secondary antibodies. The primary antibody was diluted in a ratio 1:500.
The secondary antibody was goat-anti-rabbit IgG (H+L)-HRP conjugated (BioRad170-6515) antibody (1:3000), detected with an ECL western blot detection system (Amersham Biosciences).
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed as previously described (21) . Briefly, cross-linked chromatin was prepared from HEK293 cells transfected with 3XFLAG-CMV-7.1-ZNF224 or Figure 7 . Modulation of apoptosis-regulating genes by ara-C. (A) RT-qPCR analysis of mRNA levels in K562 cells treated with 1 mM ara-C for 72 h. NT: untreated K562 cells collected at 72 h used as control. mRNA level of matrin3 was measured to demonstrate the specificity of ara-C effect on apoptosisregulating genes. Error bars represent standard deviations of three independent experiments. * P , 0.05 versus control; * * P ¼ 0.006 versus control; ns, not significant. (B) Total protein extracts were analyzed by western blot with the indicated antibodies. G3PDH was used to monitor equal loading conditions. One representative result out of three performed is presented. Molecular weight to the left. (C) RT-qPCR analysis of mRNA levels of pools of K562 cells silenced for ZNF224 and treated with 1 mM ara-C for 72 h (ZNF224 shRNA+ara-C 1 mM) or of pools of K562 cells stably transfected with scrambled shRNA treated with 1 mM ara-C for 72 h (scrambled shRNA+ara-C 1 mM) used as negative control. Error bars represent standard deviations of two independent experiments. * P , 0.05 versus scrambled shRNA treated with ara-C. pcDNA3WT1(-KTS), or co-transfected with 3XFLAG-CMV-7.1-ZNF224 and pcDNA3WT1(-KTS). Briefly, 5 × 10 7 cells were cross-linked with 1% of fixing solution (11% HCHO, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM HEPES pH 8.0) and harvested in 1.5 ml of cell lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% Nonidet P-40) with protease inhibitors (1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml aprotinin and 1 mg/ml pepstatin A). Nuclei were collected and resuspended in 300 ml of nuclear lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 0.8% SDS and protease inhibitors). The DNA was sheared by sonication to an average length between 200 and 1000 bp. Sonicated DNA was diluted 3-fold in dilution buffer (10 mM TrisHCl, pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 140 mM NaCl, protease inhibitors) and precleared with protein A/G plus-agarose (Santa Cruz Biotechnology) at 48C for 1 h. The precleared extract obtained from cells transfected with 3XFLAG-CMV-7.1-ZNF224 or co-transfected with 3XFLAG-CMV-7.1-ZNF224 and pcDNA3WT1(-KTS) was divided in two aliquots. One aliquot was incubated with 3 mg of FLAG M2 mouse antibody (Sigma-Aldrich), and the other was incubated with 3 mg of anti-mouse IgG (Sigma-Aldrich), used as control. The precleared extract obtained from cells transfected with pcDNA3WT1(-KTS) was divided in two aliquots and incubated with 5 mg of rabbit anti-WT1 antibody (C19 Santa Cruz Biotechnology), or with 5 mg of anti-rabbit IgG (Sigma-Aldrich), used as control.
Beads were collected by centrifugation and then washed three times with washing buffer P1 (30 mM NaCl, 50 mM Tris-HCl pH 8.0, 1 mM EDTA, 10%glycerol, 0.1% Nonidet P-40, protease inhibitors), twice with washing buffer P2 (50 Mm Tris -HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1% Nonidet P-40, protease inhibitors) and twice with TE buffer (1 mM Na-EDTA, 10 mM Tris-HCl pH8.0). The first supernatant of the IgG control served as the total input control for the PCR analysis effectiveness. The beads were taken up in 100 ml of TE. 1 mg of RNase was added, and cross-links were reversed at 658C overnight. The next day, samples were adjusted to 0.5% SDS and 0.5 mg/ml proteinase K and incubated for 3 h at 508C. DNA was purified by phenol -chloroform extraction. ChIP samples were then analyzed by PCR using 2 ml of immunoprecipitated material, the input control diluted in a ratio 1:200, and specific primers for: Bax (Fw 5 ′ agatgctcattggacagtcacg-3 ′ , Rev 5 ′ -gagtttctgcccctcagtgct-3 ′ ); Bak (Fw 5 ′ -gatggagtcttgcactgt cacc-3 ′ , Rev 5 ′ -ttctggctaacatggtgaaacc-3 ′ ); bag3 (Fw 5 ′ -agtcc agctcgtccggcttc-3 ′ , Rev 5 ′ -ggccagttgctacctccct-3 ′ ); A1/Bfl-1 primer sequences are described in (16) . Aldolase A primer sequences are described in (22) ; as control of immunoprecipitated chromatin specificity, PCR was performed using G3PDH primers (Fw 5 ′ -ggtcgtattgggcgcctggtcacca-3 ′ , Rev 5 ′ -cacacc catgacgaacatgggggc-3 ′ ). Results are representative of two independent experiments.
Analysis of viability and apoptosis by flow cytometry
Apoptosis of K562 cells, pools of K562 cells stably overexpressing ZNF224 (ZNF224-FLAG) or stably transfected with ZNF224 shRNA, pool of K562 cells retrovirally transduced for WT1( -KTS), was induced by cytosine arabinoside (ara-C) (Sigma-Aldrich). To this aim, cells were plated at a density of 2.5 × 10 5 /well in 12-well plates. Cell number was counted in a Bürker chamber and viability was determined by trypan blue exclusion.
For assessment of apoptosis, 2 × 10 5 cells were stained with propidium iodide (Sigma-Aldrich) and analyzed by flow cytometry as described (40) .
For annexin V staining, 3 × 10 5 cells were rinsed twice in cold PBS with Ca 2+ and Mg 2+ , than was resuspending in cold annexin V-binding buffer (5 M NaCl, 1 M CaCl 2 , 1 M HEPES buffer/NaOH pH 7.4) and stained with Annexin V-APC (550474, BD Pharmingen), DAPI (4 ′ ,6-diamidino-2-phenylindole) (D9564, Sigma-Aldrich), and 7AAD (7-amino-actinomycin) (559925, BD Pharmingen). This allows for the discrimination of live cells (DAPI impermeable) from apoptotic cells (annexin V and DAPI positive cells) and necrotic cells (7AAD and DAPI positive cells). Following incubation on shaker in the dark for 15 min at 48C, cells were analyzed on an FACS Aria flow cytometer (BD Biosciences Immunocytometry System).
